Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (Also Known as the Montelukast Trial in Sickle Cell Anemia)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 2
- 主要终点
- Change in Soluble Vascular Cell Adhesion Molecule-1 (sVCAM)
研究概览
简要总结
In this feasibility trial, the investigators will compare participants treated with montelukast and hydroxyurea to those treated with placebo and hydroxyurea for a total of 8 weeks.
详细描述
The primary hypothesis for this trial is that montelukast adds efficacy to hydroxyurea therapy for improving vaso-occlusion when compared to hydroxyurea alone. The following specific aims will be tested in adolescents and adults with sickle cell disease (SCD):
Aim 1. To determine whether montelukast versus placebo added to hydroxyurea will improve markers of vaso-occlusion-associated tissue injury in adolescents and adults with sickle cell disease.
Aim 2. To evaluate physiologic effects of montelukast versus placebo added to hydroxyurea in adolescents and adults with sickle cell disease.
Subaim 2A. To determine if montelukast versus placebo added to hydroxyurea will improve lung function in adolescents and adults with sickle cell disease.
Subaim 2B. To determine if montelukast versus placebo added to hydroxyurea will improve forearm microvascular blood flow in adolescents and adults with sickle cell disease, respectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 16 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of HbSS, or HbSβ-thalassemia0, confirmed by hemoglobin analysis
- •Males and females age 16 years to 70 years old
- •Greater than 2 episodes of pain in the last 12 months
- •On a stable dose of hydroxyurea for at least 2 months and a stable hemoglobin
排除标准
- •Judged not likely to be study compliant by his/her hematologist
- •History of adverse reaction to montelukast or any of the components of montelukast
- •Have used medications known to interact with montelukast such as rifampin, phenobarbital, and gemfibrozil within 4 weeks of enrollment
- •Currently being treated with a leukotriene antagonist (montelukast or zileuton) or have used montelukast/zileuton within the last 60 days
- •Chronic blood transfusion therapy defined as regularly scheduled transfusions.
- •Hemoglobin A greater than15% on hemoglobin analysis
- •Individuals with a current physician diagnosis of asthma (within last 12 months) or requires continuous supplemental oxygen, or predicted or current use of asthma medications (inhaled corticosteroids, but participants taking bronchodilators will be allowed to participate).
- •Current participation in another therapeutic trial for SCD
- •Known current pregnancy
- •Known history of HIV
- •Serum creatinine greater than 3 times the site's upper limit of normal
研究组 & 干预措施
Montelukast added to Hydroxyurea
Oral montelukast therapy taken daily for eight weeks with current hydroxyurea regiment
干预措施: Montelukast added to Hydroxyurea (Drug)
Placebo added to Hydroxyurea
Oral placebo taken daily for eight weeks with current hydroxyurea regiment
干预措施: Placebo added to Hydroxyurea (Drug)
结局指标
主要结局
Change in Soluble Vascular Cell Adhesion Molecule-1 (sVCAM)
时间窗: baseline to eight weeks
The primary outcome measure is based on a 30% reduction, which would be \~106 ng/ml reduction. The study was designed with 25 in each group in order to explore all three aims and potential confounders. However, if the investigators are not able to accrue 25 subjects in each arm, the investigators would still be able to detect a 30% difference in sVCAM with 17 subjects in each group. The 95% confidence interval for detecting a 30% difference is between 204 ng/ml and 290 ng/ml (or an 18-42% reduction in sVCAM). Importantly, the lower limit of the 95% confidence interval (18%) is still a clinically relevant reduction in sVCAM. Thus, if the investigators detect a 30% or larger difference in sVCAM in this study, the investigators will be assured that, based on the 95% confidence interval, these data are clinically important.
次要结局
未报告次要终点
研究者
Michael DeBaun
Professor of Pediatrics and Medicine, JC Peterson Endowed Chair in Pediatrics, Vice Chair for Clinical Research in Pediatrics, Director, Vanderbilt-Meharry-Matthew Walker Center for Excellence in Sickle Cell Disease
Vanderbilt University Medical Center